AstraZeneca’s (AZ’s) FluMist
nasal spray influenza vaccine
has been shown to have “no
measurable effectiveness”
according to a US Centres for
Disease Control expert panel who
has recommended it not be used
next flu season in the United States,
according to a report in Modern
Healthcare.
The product is not available in
Australia and doesn’t look like it will
get approval from the Therapeutic
Goods Administration any time
soon, given the expert panel
finding.
The company has made more
than US$200m from sales through
2015 but estimates it will lose
US$80m as a result of the decision.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jun 16
THE Australian Commission on Safety and Quality in Health Care has today launched a national Standard to improve the care of people with cognitive disabilities or impairments.
AUSTRALIAN mothers and their babies experienced some positive outcomes during the early years of the pandemic, new research from the Australian Institute of Health and Welfare (AIHW) has discovered.
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.